Cancer, Deals

After Tesaro buy, GSK wades deeper into cancer unveiling big immunotherapy deal with Germany’s Merck

/>

by — on
Updated:

GSK is muscling its way into the cancer big leagues, months after agreeing to shell out $5 billion for cancer drugmaker Tesaro. On Tuesday, the British drugmaker said it would co-develop a fusion protein immunotherapy — designed to offer fresh ways to fight difficult-to-treat cancers beyond the existing PD-1/PD-L1 class — with Germany's Merck KGaA in a deal valued up to about $4.2 billion.

In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 47,300+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,300+ biopharma pros who read Endpoints News by email every day.

Free Subscription
GMP Biomanufacturing Operator
Aldevron Fargo, ND
Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA
Visit Endpoints Careers ->